Personalizing cancer immunotherapy

BrightPath, formerly known as GreenPeptide, is moving beyond peptides to push the boundaries of cancer immunotherapy toward more personalized treatments.

Like 1 Comment
Page of
Go to the profile of Brightpath Biotherapeutics

Brightpath Biotherapeutics

BrightPath Biotherapeutics, formerly GreenPeptide, is a Japan-based clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapeutics. Our pipeline includes cancer peptide vaccine, rejuvenated T cell therapy, and immuno-modulator antibodies. Our basic business model covers research and early clinical development, followed by out-licensing to pharmaceutical companies, so we would like to take an opportunity to introduce our out-licensing candidates. We also search for in-licensing and/or research collaboration opportunities in I/O field.

No comments yet.